Highest-materiality recent filing
Xenon shareholders approve 2026 equity plan, elect directors at annual meeting
Shareholders approved the 2026 Equity Incentive Plan: 58.6M for, 27.6M against, 842K abstain.
Xenon reports positive Phase 3 X-TOLE2 data for azetukalner; NDA submission planned Q3 2026
Phase 3 X-TOLE2 met primary endpoint: median percent change in monthly FOS -53.2% (25mg) and -34.5% (15mg) vs -10.4% placebo (p<0.0001).
Xenon increases inducement equity plan share reserve from 900k to 1.175M shares
Amended 2025 Inducement Plan to raise maximum shares reserved from 900,000 to 1,175,000, a 30.6% increase.
Xenon Pharma sets 2026 annual meeting for June 2; record date April 7
Annual meeting scheduled for June 2, 2026.
Xenon Pharmaceuticals raises $707.7M in public offering of common shares and pre-funded warrants
Offered 12.2M common shares at $57.00 plus pre-funded warrants for 877,194 shares at $56.9999 each.
Xenon Phase 3 X-TOLE2 azetukalner meets primary endpoint; NDA submission Q3 2026
Primary endpoint MPC: 25mg -53.2% vs placebo -10.4% (p<0.000000000006); placebo-adjusted -42.7%, outperforming Phase 2b.
Xenon files $400M ATM equity prospectus supplement; $291M already sold under prior program
Filed prospectus supplement to register up to $400M of common shares for at-the-market (ATM) sales.
Xenon reports 2025 net loss of $345.9M; Phase 3 X-TOLE2 data expected in March 2026
Net loss $345.9M in 2025 vs $234.3M in 2024; R&D expense rose to $300.9M on azetukalner Phase 3 trials.
Xenon Pharma amends inducement plan, increases share reserve to 900,000
Amended 2025 Inducement Plan on Nov 24, 2025, increasing share reserve from 775,000 to 900,000 common shares.
Xenon Q3 net loss $90.9M, Phase 3 FOS study fully enrolled, new CFO appointed
Net loss $90.9M (vs $62.8M Q3 2024) on higher R&D spend; R&D expenses $77.1M (vs $57.0M).
Xenon names Tucker Kelly CFO with $540k salary, 225k options, 30k RSUs
Tucker Kelly appointed CFO effective Oct 15, 2025; replaces interim CFO Ian Mortimer who remains CEO.
Xenon appoints Tucker Kelly as CFO; grants 225K options, 30K RSUs
Tucker Kelly named CFO effective Oct 15, 2025; previously CFO at Deciphera (acquired by Ono for $2.4B).
Xenon Q2 net loss $84.7M; azetukalner Phase 3 X-TOLE2 enrollment complete, topline early 2026
Net loss $84.7M vs $57.9M Q2 2024; R&D expenses rose to $75.0M from $49.7M on azetukalner trials.
Xenon CFO Sherry Aulin resigns; CEO Ian Mortimer appointed interim CFO
Sherry Aulin resigned as CFO, effective June 30, 2025.
Xenon Pharmaceuticals holds 2025 Annual Meeting; all director nominees elected
All 8 director nominees elected with over 64M votes each; broker non-votes of 2.2M.
Xenon Q1 net loss $65.0M; X-TOLE2 topline data shifted to early 2026
Net loss of $65.0M (vs $47.9M Q1 2024) on higher R&D spend of $61.2M; revenue $7.5M from Neurocrine milestone.
Xenon Pharmaceuticals sets 2025 annual meeting for June 4, record date April 7
Annual meeting of shareholders scheduled for June 4, 2025.
Xenon Pharmaceuticals dismisses KPMG, appoints PwC as independent auditor
Audit Committee dismissed KPMG as independent registered public accounting firm on March 3, 2025.
Xenon reports 2024 net loss $234.3M; CFO resigns; Phase 3 azetukalner FOS data due H2 2025
Net loss for 2024 was $234.3M ($65.7M Q4), vs $182.4M in 2023; R&D spend rose to $210.4M.
Xenon Pharmaceuticals CCO Christopher Von Seggern departs; consulting agreement through May 2025
Christopher Von Seggern ceased as Chief Commercial Officer on January 17, 2025.
Xenon Q3 2024 net loss $62.8M; X-TOLE2 topline data expected H2 2025; COO appointed
Net loss of $62.8M for Q3 2024, compared to $48.5M in Q3 2023; R&D expenses rose to $57.0M.
Xenon reports Q2 net loss of $57.9M; cash $850.6M; Phase 3 epilepsy data H2 2025
Net loss for Q2 2024 was $57.9M, compared to $47.5M in Q2 2023.
Shareholders approve all proposals at annual meeting including 5.2M share increase to equity plan
All 8 director nominees elected, e.g., Dawn Svoronos 61.5M For vs 4.5M Against; broker non-votes 2.6M.
Xenon Q1 net loss $47.9M; MDD Phase 3 on track for H2 2024 start
Net loss of $47.9M for Q1 2024, up from $41.7M in Q1 2023; cash and securities $885.4M.
Xenon Pharmaceuticals chair Simon Pimstone and director Mohammad Azab not standing for re-election
Chair Simon Pimstone and board member Mohammad Azab will not stand for re-election at 2024 annual meeting.
Xenon sets June 4, 2024 annual meeting; record date April 5
Annual meeting of shareholders scheduled for June 4, 2024.
Xenon Pharma reports FY2023 net loss $182.4M, cash $930.9M; XEN1101 Phase 3 on track
Net loss of $44.7M in Q4 2023 and $182.4M for FY2023, vs $37.4M and $125.4M in 2022.
Net proceeds ~$281.6M from sale of 8,461,542 common shares and 769,230 pre-funded warrants at $32.50 per share/warrant.
Xenon reports Phase 2 XEN1101 MDD trial misses primary endpoint but hits secondary measures
MADRS at week 6: placebo reduction 13.90; XEN1101 20 mg reduction 16.94 (p=0.135), not statistically significant.
Xenon partner Neurocrine's Phase 2 trial of NBI-921352 in focal seizures fails
Phase 2 study of NBI-921352 in adult focal onset seizures failed to show meaningful seizure reduction.
Xenon Q3 net loss $48.5M; XEN1101 MDD trial topline due late Nov–mid Dec
Net loss $48.5M in Q3 2023 vs $37.2M in Q3 2022; cash $639.1M, funding operations into 2026.
Xenon reports Q2 net loss $47.5M; XEN1101 MDD trial fully enrolled with data expected late Nov-Dec
Q2 net loss $47.5M vs $31.2M YoY; R&D expenses doubled to $44.0M on XEN1101 Phase 3 and MDD trials.
Xenon appoints Dr. Gillian Cannon and Justin Gover to Board of Directors
Dr. Cannon brings 30+ years of pharma experience; held senior roles at Merck, UCB, Otsuka, and Roivant.
Xenon Pharmaceuticals announces results of 2023 annual meeting; all proposals approved
All 8 director nominees elected; highest vote count 50.7M (Svoronos, Gannon), lowest 48.5M (Machado).
Xenon reports Q1 2023 net loss $41.7M; advances XEN1101 Phase 3 epilepsy trials
Net loss $41.7M ($0.66 per share) vs $19.7M in Q1 2022; no revenue recognized.
CEO Ian Mortimer: 2022 non-equity bonus $343,422; 2023 base salary $665,000.
Xenon sets June 1, 2023 annual meeting; record date April 4, 2023
Annual meeting scheduled for June 1, 2023.
Xenon reports FY2022 net loss of $125.4M; cash $720.8M; XEN1101 Phase 3 ongoing
Net loss of $125.4M for FY2022 vs $78.9M in 2021; Q4 net loss $37.4M.
Xenon Q3 net loss $37.2M; launches XEN1101 Phase 3 epilepsy program
Revenue $0.1M vs $8.1M YoY; no Neurocrine milestone in Q3 2022.
Xenon Pharma appoints Andrea DiFabio as Chief Legal Officer and Corporate Secretary
Andrea DiFabio joined Xenon as Chief Legal Officer and Corporate Secretary effective Nov 7, 2022.
Xenon Pharma Q2 net loss $31.2M; XEN1101 Phase 3 on track for H2 2022
Net loss of $31.2M for Q2 2022, up from $22.1M in Q2 2021.
Offering of 7,868,854 common shares and pre-funded warrants for 327,868 shares at $30.50/share and $30.4999/warrant.
Xenon announces positive FDA EOP2 meeting for XEN1101; Phase 3 to start H2 2022
FDA aligned on key Phase 3 elements; NDA submission planned after completion of X-TOLE2 trial plus existing Phase 2b data.
Xenon shareholders approve 5.3M share equity plan increase; all director nominees elected
Amendment to 2014 Equity Plan approved: 35.6M for, 6.2M against, 5.1M broker non-votes.
Xenon Q1 net loss $19.7M; XEN1101 Phase 3 on track for H2 2022
Net loss $19.7M vs $15.8M YoY; revenue $8.8M, up from $4.4M on Neurocrine milestone.
Xenon issues 1.016M common shares on conversion of all Series 1 Preferred held by BVF Partners
Converted 1,016,000 Series 1 Preferred Shares into 1,016,000 common shares.
Xenon: director Hayden not standing for re-election; Pimstone to become Chair; exec comp approved
Michael Hayden will not stand for re-election at June 1, 2022 annual meeting; no disagreement with company.
Xenon reports FY2021 net loss $78.9M; XEN1101 Phase 3 expected H2 2022
Net loss $78.9M vs $28.8M in 2020; revenue $18.4M vs $32.2M.
Xenon Pharmaceuticals enters amended ATM equity offering agreement for up to $250M
Amendment to August 2020 ATM sales agreement with Jefferies and Stifel, filed March 1, 2022.
FDA accepted protocol amendment to expand Phase 2 study of NBI-921352 to children aged 2–11 with SCN8A-DEE.
On February 24, 2025, Ms. Sherry Aulin notified the Company of her decision to resign as Chief Financial Officer, effective June 30, 2025, for personal reasons.
On January 17, 2025, Christopher Von Seggern ceased to be the Chief Commercial Officer of Xenon Pharmaceuticals Inc. (the “Company”) and departed the Company as of such date.
On April 15, 2024, Dr. Simon Pimstone, chair of the board of directors (the “Board”) of Xenon Pharmaceuticals Inc. (the “Company”), and Dr. Mohammad Azab, a member of the Board, each informed the Company of their respective decisions not to stand for re-election to the Board at the Company’s 2024 annual meeting of shareholders (the “AGM”).
On April 15, 2024, Dr. Simon Pimstone, chair of the board of directors (the “Board”) of Xenon Pharmaceuticals Inc. (the “Company”), and Dr. Mohammad Azab, a member of the Board, each informed the Company of their respective decisions not to stand for re-election to the Board at the Company’s 2024 annual meeting of shareholders (the “AGM”).
appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.
appointed Dr. Gillian Cannon and Mr. Justin Gover as directors of the Company, effective as of August 8, 2023.
appointed Dr. Pimstone, current Executive Chair of the Board, as Chair of the Board, effective upon and subject to his re-election as a director at the Annual Meeting.
Michael Hayden, notified the Board that he would not stand for re-election as a director of the Board at the Annual Meeting.
Max materiality 0.90 · Median 0.57 · Most common event earnings